Navigation Links
Idenix Reports Advancement of HCV Development Pipeline
Date:1/9/2012

X184 or any other drug candidate; the successful development of novel combinations of direct-acting antivirals for the treatment of hepatitis C; the likelihood and success of any future clinical trials involving our drug candidates; and expectations with respect to funding of operations and future cash balances. Actual results may differ materially from those indicated by such forward-looking statements as a result of risks and uncertainties, including but not limited to the following: there can be no guarantees that the Company will advance any clinical product candidate or other component of its potential pipeline to the clinic, to the regulatory process or to commercialization; management's expectations could be affected by unexpected regulatory actions or delays; uncertainties relating to, or unsuccessful results of, clinical trials, including additional data relating to the ongoing clinical trials evaluating its product candidates; the Company's ability to obtain additional funding required to conduct its research, development and commercialization activities; the Company's dependence on its collaboration with Novartis Pharma AG; changes in the Company's business plan or objectives; the ability of the Company to attract and retain qualified personnel; competition in general; and the Company's ability to obtain, maintain and enforce patent and other intellectual property protection for its product candidates and its discoveries. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. These and other risks which may impact management's expectations are described in greater detail under the heading "Risk Factors" in the Company's quarterly report on Form 10-Q for the quarter ended September 30, 2011, as filed with the Securities and Exchange Commission (SEC) and in any subseq
'/>"/>
SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Idenix to Host Conference Call Discussing Third Quarter 2008 Financial Results
2. Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results
3. Idenix Pharmaceuticals to Present at Deutsche Banks 2008 Biotech Boston Confab
4. Idenix Pharmaceuticals to Present at the JP Morgan 27th Annual Healthcare Conference
5. Idenix to Host Conference Call Discussing Fourth Quarter 2008 Financial Results
6. Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results
7. Idenix Announces Data Presentations from Three HCV Discovery and Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL)
8. Idenix Pharmaceuticals to Present at the Canaccord Adams Hepatitis C Conference
9. Idenix Pharmaceuticals Reports Data From Three Hepatitis C Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver
10. Idenix Pharmaceuticals Reports First Quarter Financial Results
11. Idenix Pharmaceuticals to Present at The Deutsche Bank 2009 Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... 21, 2015 Invetech , a ... automation, and contract manufacturing, and  NanoCellect Biomedical, ... and cell sorting technology for life science researchers, ... flow cytometry platform. Headquartered in ... developed a microchip-based cell sorting technology. NanoCellect,s flow ...
(Date:4/21/2015)... 21, 2015  scPharmaceuticals, Inc., a privately ... for subcutaneous delivery, announced today that it ... investigational proprietary drug product, Furosemide Injection Solution, ... congestive heart failure. Concurrently with ... proprietary patch pump.  The patch pump is ...
(Date:4/21/2015)... (UK) (PRWEB) April 21, 2015 ... and its clinical applications will be presented ... include engineers, scientists, regulators and clinicians from ... meeting is sponsored by Invibio Biomaterial Solutions. ... biomaterials, a specialist in manufacturing and R&D ...
(Date:4/20/2015)... Columbia and MENLO PARK, ... DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and ... and commercializing proven cancer therapies in new orphan ... the 106th Annual Meeting of the American ... on the potential for its lead product candidate ...
Breaking Biology Technology:NanoCellect And Invetech Announce Collaboration To Develop Novel Flow Cytometry Platform For Cell Sorting And Analysis 2NanoCellect And Invetech Announce Collaboration To Develop Novel Flow Cytometry Platform For Cell Sorting And Analysis 3scPharmaceuticals Announces Start of Pivotal Trial for Novel Furosemide Solution for Subcutaneous Delivery 2scPharmaceuticals Announces Start of Pivotal Trial for Novel Furosemide Solution for Subcutaneous Delivery 32nd International PEEK Meeting: Invibio Biomaterial Solutions spearheads medical research for implantable PEEK polymer devices 22nd International PEEK Meeting: Invibio Biomaterial Solutions spearheads medical research for implantable PEEK polymer devices 3DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 2DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 3DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 4DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 5
... Sept. 19 /Xinhua-PRNewswire-FirstCall/ -- China Sky One,Medical, Inc. ... CSKI ), a,leading fully integrated pharmaceutical company ... ("PRC"), announced today that it,has successfully completed the ... certification, or CE mark, which indicates that,a company,s ...
... seven medical,experts in psychiatry from across the world ... action to optimize services for people with a,diagnosis ... bipolar,disorder(i)., Professor W. Wolfgang Fleischhacker, principal author ... Disorders: Clinical,Policy, and Research Challenges which was published ...
... MedNet Solutions, a global,eClinical technology company specializing ... active involvement as a speaker,sponsor and exhibitor at ... Conference, to be held Sunday, September 21 through,Wednesday, ... has invited Dr. Timothy Pratt, PhD, Chief Marketing ...
Cached Biology Technology:China Sky One Medical, Inc. Passes First Phase Examination for (CE) Certification 2China Sky One Medical, Inc. Passes First Phase Examination for (CE) Certification 3Global Psychiatrists Unite to Improve Services in Mental Health 2Global Psychiatrists Unite to Improve Services in Mental Health 3MedNet Solutions to Speak, Sponsor and Exhibit at the 2008 Society of Clinical Data Management Annual Conference in Dallas 2
(Date:4/20/2015)... , April 20, 2015 The ... Glenbeigh Records Management (GRM), Ireland,s ... Dubai Islamic Bank. Having built up an impressive track record ... a leading player within the records management sector in ... to double is GCC staffbase and employ a further eight ...
(Date:4/13/2015)... YORK , April 13, 2015 ... by TechSci Research, "Global Biometrics Market Forecast & Opportunities, ... register a CAGR of around 14% till 2020. ... governments for large scale implementation and review of ... and launch of new products with greater efficiency, ...
(Date:4/8/2015)... , April 8, 2015  Infinisource, a ... and services, and Morpho, a leading supplier of ... to produce the market,s most advanced biometrically-enabled time ... iSolved NXG time clock is setting a bold, ... labor data for the small and mid-size employer. ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3
... to double the odds a teenage girl will begin smoking, ... who analyzed the dieting and smoking practices of 8,000 adolescents, ... also less likely than girls to diet, according to findings ... Dieting was a significant predictor of initiation of regular smoking ...
... 2007- As of late, many uncertainties have been sprouting ... wondering if precision agricultural technologies can improve crop yield ... asking a number of questions from, which hybrid should ... applying nitrogen fertilizer at a uniform rate produce a ...
... Chicago researchers have identified new sites on the ... delivered to treat infections. "The primary challenge ... by the pathogens which became resistant to antibiotics," ... UIC,s Center for Pharmaceutical Biotechnology and lead investigator ...
Cached Biology News:Girls who begin dieting twice as likely to start smoking 2Girls who begin dieting twice as likely to start smoking 3The 5 Ws of corn production 2UIC researchers find promising new targets for antibiotics 2
... Blot Processing Standard Tray (3 per ... gel staining and blot processing.Automated staining ... for proteins and nucleic acid analysis.Prepares ... and chromogenic detection.Programmable control of protocol, ...
DITHIOTHREITOL, 150UMOL, 1 EA. Dithiothreitol (DTT), 0.1 M Solution:, *0.1 M solution of DTT in high purity dH2O., *0.2 m filtered., *Storage: -20C. Category: SEQUENASE....
GOAT ANTI HUMAN PARAINFLUENZA VIRUS 2+3...
75 x 25 mm; sterile, recommended for immunohistochemistry of cell lines growing in suspension, Poly-D-Lysine coated, glass slides with polystyrene vessel, lid and safety removal tool...
Biology Products: